One trading day after the Dow Jones Industrial Average scored its first triple-digit gain day since the beginning of the year and the index notched a tripled-digit decline of 130 points, a downturn almost completely erased the previous day’s advance. While Europe’s troubles weighed heavily on the Dow, the following three stocks ignored what was going on overseas and put up some worthy numbers.
| Company | % Gain |
|---|---|
| Sonus Networks (NASDAQ:SONS) | 20.2% |
| Delcath Systems (NASDAQ:DCTH) | 8% |
| China Digital TV (NYSE:STV) | 7.6% |
Resist the urge to high-five everyone in the cubicles next to you. Smart investors won’t celebrate until they know why their stock surged, because without a fundamental basis for the bounce, these stocks could just as quickly make the return trip down.
The news that Oracle Corporation (NASDAQ:ORCL) was buying Acme Packet, Inc. (NASDAQ:APKT) for $2.1 billion sent the entire network gear industry soaring on hopes that there will be more buyouts coming down the road. Sonus Networks’ gain almost matched the advance of Acme itself, so hopeful were investors that it’s the next logical choice, but BroadSoft Inc (NASDAQ:BSFT) was up 10% as well.
It’s not a completely unreasonable supposition, but Acme had certain attributes — like profitability — that Sonus doesn’t. Moreover, Sonus bought Network Equipment Technologies last year, a manufacturer of Internet communications equipment for both government and the private sector, in an effort to beef up its presence in the enterprise SBC market. SBCs set up Internet calls over landline and wireless phone networks, and that simply means that as more information gets routed over the Internet, it’ll need robust gatekeepers to regulate the flow of traffic from outside networks. But analysts thought it overpaid for the purchase, and that will add to its pressures.
Let me know in the comments box below who you think might be willing to step up to the plate and make a bid for Sonus Networks.
The pressure’s on
German regulators said the country’s cancer centers could receive reimbursement from insurance companies for the chemotherapy procedure Chemostat developed by Delcath Systems. While it gives them a foot in the door in having the procedure more widely used and accepted, the decision doesn’t mandate reimbursement, just that the centers can negotiate with the insurers. While a mandate might have been optimal, the designation does open pathways for broader adoption, particularly as Germany is the largest market in Europe for the procedure.
Chemostat is a drug delivery system that serves to treat tumors in the liver. The liver’s blood outflow is isolated from the body’s other organs and saturated with chemotherapy at concentrated levels. With the recent implosion of Celsion Corporation (NASDAQ:CLSN) after its late-stage trial failed on a different liver cancer treatment, Delcath is now the specialist investors are watching closely. The news out of Germany could give them some hope it will be able to build on this success, but, as with most small biotechs, there are still risks ahead.
Say no more
There was no company-specific news to account for the jump in China Digital TV’s shares, other than its announcement that it will report fourth-quarter and full year 2012 results later this month. Perhaps investors are expecting earnings to come in well ahead of expectations.
